Select Page

420 with CNW — Researchers Explore Combining Psilocybin, Cannabinoids in New Therapeutic Formulations

Cannabis News Wire, Media Partners

This post is presented by our media partner Cannabis News Wire

View the original article here.


The convergence of cannabinoids and psilocybin in a unified formulation to address physical and psychological well-being has moved closer to realization as highlighted in a patent filed by a prominent cannabinoid laboratory called CaaMTech. Situated in Issaquah, Washington, just under 20 miles southeast of Seattle, CaaMTech is conducting an analysis of the mutual interactions between these two compounds and the specific outcomes they can yield in terms of physical and mental health.

Presently, the company’s refined psilocybin-cannabinoid formulation is still in the early stages of development. This patent progress comes at a time when the availability of genetic information on marijuana and psilocybin is increasing, which presents opportunities to explore novel ways in which these substances can collaborate, potentially resulting in the creation of innovative commercial offerings.

For example, the combination of marijuana and psilocybin has demonstrated tumor reduction in the case report of a 49-year-old woman with breast cancer. This discovery has prompted researchers to conclude that mounting empirical and anecdotal evidence supports the therapeutic potential of cannabinoids as well as psychedelics in diminishing tumor growth while also providing relief from pain and psychological distress associated with cancer and chemo.

Researchers now envision a comprehensive solution to address extreme mental health disorders and inflammation by harnessing the beneficial properties of both substances. One potential approach involves incorporating psilocybin with a minor cannabinoid such as cannabichromene (CBC), which is abundantly present in cannabis plants. This amalgamation could potentially result in a one-time treatment option.

Daniel McQueen, executive director of the Boulder, Colorado-based Center for Medicinal Mindfulness and author of a book titled “Psychedelic Cannabis,” has been facilitating marijuana-assisted psychedelic therapy at the organization. This therapy involves overseeing individual psychedelic cannabis and ketamine experiences alongside guided meditation, personal coaching, educational classes, as well as community support.

McQueen agrees that the creation of a psilocybin-marijuana pill or combination compound is entirely feasible. Nevertheless, there are significant obstacles to overcome in developing such a compound. Cannabinoids and psychedelics interact with distinct receptors in the brain. THC, a cannabinoid, predominantly binds to CB1 receptors, while CBC primarily binds to CB2 receptors. On the other hand, psilocybin, a psychedelic, primarily binds to 5-HT2A serotonin receptors.

However, research has indicated that CBD, one of the abundant cannabinoids, interacts with serotonin’s receptors, and when serotonin is coupled with a CB2 cannabinoid receptor, this combination can produce effects that none of the receptors can achieve independently. A study conducted by Spanish scientists in 2022 focusing on ischemia in newborn piglets revealed that CBD activates serotonin receptors, leading to neuroprotective effects.

Researchers continue to diligently seek improved solutions to address mental health concerns, regardless of the substances involved.

Other research teams, such as the team at IGC Pharma Inc. (NYSE American: IGC), are focusing on developing therapeutics from THC and other cannabinoids for use in the mainstream healthcare system.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published:

Do you have questions or are you interested in working with CNW420? Ask our Editor

Denver, Colorado
303.498.7722 Office

CNW420 is part of the InvestorBrandNetwork.

This post was originally published by our media partner here.